Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAQE in Hepatocellular Carcinoma
NCT05842174Phase 2Recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Apr 2026
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of hydroxychloroquine in hepatocellular carcinoma (HCC) (2 arms), sponsored by VA Office of Research & Development. Primary endpoint: Local Progression Free Survival at 6 months. Started Apr 2026; status: recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05842174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05842174.